Memorandum of Understanding
between
the Ministry of Food and Drug Safety
of the Republic of Korea
and
the Emirates Drug Establishment
of the United Arab Emirates
on
Comprehensive Cooperation
in the Field of Biohealth

The Ministry of Food and Drug Safety of the Republic of Korea (hereinafter referred to as the "MFDS") and the Emirates Drug Establishment of the United Arab Emirates (hereinafter referred to as the "EDE") (hereinafter collectively referred to as the "Participants" and individually as a "Participant"),

Desiring to explore new areas of comprehensive and strategic cooperation in the field of medical products, including pharmaceuticals, biopharmaceuticals (including vaccines), and medical devices (including in vitro diagnostic devices, artificial intelligence (AI)-based or digital medical devices), and cosmetics (hereinafter collectively referred to as "biohealth")

Have reached the following understanding:

PARAGRAPH 1
Purpose

The purpose of this Memorandum of Understanding (hereinafter referred to as the "MoU") is to establish and strengthen a cooperative system between the Participants based on the principles of equality and reciprocity, emphasize the importance of safety and innovation in the biohealth sector, and promote ongoing and comprehensive cooperation and exchanges between the Participants in the field of biohealth.

PARAGRAPH 2
Areas of Cooperation

The areas in which the Participants will cooperate may include, but are not limited to, the following:

a) joint programs and training : organization of joint seminars, workshops, and training programs on regulatory science, AI, and other relevant topics in the field of biohealth;
b) exchange of information and expertise : sharing of regulatory information, scientific data, and best practices in the areas covered by this MoU;
c) capacity building : promotion of expert exchanges and training activities to strengthen technical and regulatory expertise;

d) research and development collaboration : exploration of opportunities for joint research projects and studies related to regulatory innovation, digital transformation, and product safety; and
e) support for new technology cooperative projects : support for the development of joint cooperative programs and projects for the development of new technology-related cooperative activities.

PARAGRAPH 3
Establishment of Cooperative System

1. To implement the MoU, the Participants may establish consultative bodies or cooperative mechanisms including joint working groups and high-level meetings. The details regarding the operation of this cooperative system will be separately discussed by the Participants.

2. The working group will consist of director-level officials and other relevant personnel designated by the Participants. It will be responsible for developing detailed plans, monitoring progress, discussing policy issues, promoting personnel exchanges and training, and sharing information and technology. Meetings will be held in person or online.

3. The high-level meetings will be held to review the strategic direction of the Participants' cooperative projects, key policy matters, and the agenda and performance management of the working group. The high-level meetings will consist of director general-level officials from the Participants and will be held at least once a year.

4. The Participants will convene strategy meetings co-chaired by the heads of the Participants to engage in forward-looking discussions based on regulatory science, such as advancing biohealth innovation in the two countries and exploring expanded export opportunities for biohealth companies from the two countries.

PARAGRAPH 4
Confidentiality

Any information acquired as a result of the cooperative activities described in Paragraph 2 will be used exclusively by the Participants. Such information may be disclosed to third parties or the public by a Participant only with the prior written consent of the other Participant.

PARAGRAPH 5
Changes to Relevant Laws and Regulations

The Participants will promptly notify each other of any changes in their respective laws, regulations, policies, or procedures that may affect their ability to carry out the activities under this MoU.

PARAGRAPH 6
Financing

Each Participant will bear its own costs necessary to implement the activities under this MoU, unless otherwise jointly determined by the Participants.

PARAGRAPH 7
Contact Points

1. For the effective implementation of the cooperative activities under this MoU, the Participants designate the following contact points to facilitate communication between the Participants:

   a) for the MFDS: the International Cooperation Office;
   b) for the EDE: Strategic Partnerships Department.

2. Each Participant will notify the other Participant in case of any change to its contact point.

PARAGRAPH 8
Resolution of Differences

Any differences arising from the interpretation, application, or implementation of this MoU will be resolved amicably through consultations between the Participants.

PARAGRAPH 9
Status of the MoU

1. This MoU is not intended to create any legally binding obligations for the Participants under domestic or international law. This MoU will not affect rights and obligations of two countries arising from international conventions or agreements to which either of them is party.

2. This MoU will be carried out in accordance with the respective laws and regulations of the two countries and subject to the availability of appropriated funds and human resources of the Participants.

PARAGRAPH 10
Entry into Effect, Duration, Termination, and Amendment

1. This MoU will come into effect on the date of its signature by the Participants.

2. This MoU will be effective for five (5) years and will be automatically renewed for successive five-year periods, unless either Participant notifies the other Participant, at any

time, in writing, of its intention not to renew this MoU, provided that such notice is communicated at least six (6) months in advance of the expiration.

3. This MoU may also be terminated at any time upon mutual written consent of the Participants.

4. This MoU may be amended at any time by mutual written consent of the Participants.

5. The expiration or termination of this MoU will not affect any commitments or ongoing activities under this MoU, unless otherwise jointly decided by the Participants.

6. Upon the entry into effect of this MoU, the Memorandum of Understanding between the Ministry of Food and Drug Safety of the Republic of Korea and the Emirates Drug Establishment of the United Arab Emirates on Cooperation in the Field of Medical Products, signed on the 4th day of September, 2024, will be terminated and replaced by this MoU.

Signed in duplicate at Abu Dhabi, on the 18th day of November, 2025, in the Korean, Arabic and English languages, all the text being equally valid. In the case of discrepancy in the interpretation of the text, the English text will prevail.

For the Ministry of Food and Drug Safety of the Republic of Korea	For the Emirates Drug Establishment of the United Arab Emirates
오 유 경	
Yu-Kyoung OH	Saeed Bin Mubarak Al Hajeri
Minister	Minister of State and Chairman of Emirate Drug Establishment Board